Trial Profile
A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2010
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Aug 2009 New trial record